Skip to main content
Premium Trial:

Request an Annual Quote

ProQinase, Mercachem Share Grant to Develop Epigenetics Platform

NEW YORK (GenomeWeb News) – ProQinase and Mercachem on Monday said they have been awarded €2.5 million ($3.2 million) to develop a new drug discovery platform targeting epigenetic enzyme families.

The three-year grant from the European Union's Eurostars program will be used to develop the platform, comprising novel biological and pharmacological assays, along with new chemical space libraries targeted against the most prominent epigenetic enzyme families, the partners said.

ProQinase and Mercachem will establish biochemical, cell-based, and in vivo test systems and develop scaffold-based compound libraries "that qualify for hit generation" and then for lead finding and optimization.

"Similar to protein kinases, epigenetic enzymes belong to enzyme families of which some members are deregulated in cancer representing promising oncology intervention points," Michael Kubbutat, head of drug develop for ProQinase, said in a statement. "To allow most beneficial epigenetic therapies, novel epigenetic drugs should only block the action of oncogenic, (but not other) members of the respective enzyme family.

"Hence, we are convinced that our approach that comprises early drug profiling against on- and off-targets of epigenetic enzyme families and a stepwise improvement of inhibitory profiles will allow us to generate improved lead compounds and pre-clinical candidates," he said.

ProQinase is a contract service provider based in Freiburg, Germany. Mercachem is headquartered in Nijmegen, the Netherlands and is a contract research organization.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.